The short version

Here's the fact almost no comparison leads with: Mounjaro and Zepbound are the same drug. Both are tirzepatide, both are made by Eli Lilly, both come in the same six dose strengths (2.5 mg up to 15 mg), and milligram-for-milligram they are interchangeable in the body. The only real difference is the label: Mounjaro is FDA-approved for type 2 diabetes, and Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea. That one difference — which indication each brand carries — is what quietly decides everything that actually matters to you: whether insurance covers it, what you pay cash, and which one you can legitimately be prescribed. So "which is better for weight loss?" is the wrong question, because the answer is "they're the identical molecule." The right questions are about access and price, and this guide answers those with the real 2026 numbers. None of it is medical advice; your prescriber decides what's appropriate for you.

If you've been researching tirzepatide, you've run into both names and probably come away confused. One article treats Mounjaro and Zepbound as rivals to be scored against each other; another mentions in passing that they're "basically the same"; a third compares their weight-loss numbers as if they came from different drugs. The confusion is understandable, because Eli Lilly deliberately sells the same medicine under two brand names for two different approved uses — and the pricing, coverage, and prescribing rules attached to each name genuinely differ, even though the stuff inside the pen does not.

This guide clears it up honestly. We'll start with the single most important thing to understand — that these are the same molecule — because it reframes the entire decision. Then we'll get into the differences that are real and that will determine your experience and your bill: the FDA labels, insurance coverage, cash prices, and who can legitimately get which. Where a number comes from a trial, a regulator, or a manufacturer, we cite it, and where a figure moves around — prices especially — we say so and tell you where to confirm it. The goal is that by the end you know exactly which brand your situation points to and why.

One note on scope before we start. This compares the two branded tirzepatide products and the real-world routes to getting them. It is not a prescription, a diagnosis, or a substitute for a clinician. Tirzepatide is a serious medication with real benefits and real risks, and the most important decision here isn't Mounjaro-versus-Zepbound — it's doing this with a genuine prescriber who takes a real history. With that said, let's start with the fact that changes everything.

The one thing to understand first: it's the same drug

Mounjaro and Zepbound contain the exact same active ingredient — tirzepatide — made by the same manufacturer, Eli Lilly, in the same dose strengths. There is no chemical difference between 5 mg of Mounjaro and 5 mg of Zepbound. The MedlinePlus drug information for tirzepatide describes a single molecule used under both brand names. If a pharmacist handed you an unlabeled 10 mg dose of each, nothing could distinguish them, because there is nothing to distinguish.

This matters enormously, because it collapses the entire premise of most "Mounjaro vs Zepbound" content. You cannot have a meaningful fight over which molecule produces more weight loss when it's one molecule. Any difference you see in outcomes between the two brands comes from the population studied (people with diabetes tend to lose somewhat less weight on GLP-1 drugs than people without it) and from which doses and durations each brand's trials used — not from the drug being different. Drug-for-drug, dose-for-dose, in the same person, they do the same thing.

So why two names? Because in the United States a drug is approved and marketed for specific indications — specific medical conditions — and Lilly chose to build a separate brand, label, and (crucially) a separate pricing and access system around each use. Mounjaro is the diabetes brand; Zepbound is the obesity-and-sleep-apnea brand. Same car, two trim badges, two very different window stickers. The rest of this guide is really about those window stickers, because that's where your actual experience and cost live.

 MounjaroZepbound
Active ingredientTirzepatideTirzepatide (identical)
MakerEli LillyEli Lilly
FDA-approved forType 2 diabetesChronic weight management; obstructive sleep apnea
How it worksGLP-1 + GIP dual agonistGLP-1 + GIP dual agonist (identical)
Dose strengths2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg (identical)
FormWeekly injection (pen; vials via self-pay)Weekly injection (pen; single-dose vials via self-pay)
Typically covered underDiabetes drug benefit (often covered)Anti-obesity benefit (often excluded)
Self-pay list (2026 snapshot)~$1,100/mo list; ~$499/mo self-pay~$1,086/mo list; ~$299–$449/mo self-pay vials
Best summed up asThe diabetes door to tirzepatideThe weight-loss door to tirzepatide

Indications per the FDA approvals cited below and MedlinePlus. Prices are a late-2026 self-pay snapshot from the manufacturers' official pages and change often — always confirm the current number before you commit.

Why one drug has two names

The two-brand strategy isn't arbitrary, and understanding it explains the pricing and coverage maze that follows. Tirzepatide first reached the market as a diabetes drug. The FDA approved Mounjaro in May 2022 as a once-weekly injection to improve blood sugar in adults with type 2 diabetes, on the strength of the SURPASS trial program. In those studies it didn't just lower blood sugar; it produced striking weight loss as a side effect — enough that it was obvious the molecule had a second career ahead of it.

So Lilly ran a second, separate trial program — SURMOUNT — testing the same molecule specifically for weight management in people with obesity (most of them without diabetes). Those trials succeeded, and the FDA approved the same drug under a new brand name, Zepbound, for chronic weight management in November 2023. Then, in December 2024, Zepbound picked up a second indication when the FDA approved it as the first drug for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro, meanwhile, stayed the diabetes brand.

Why not just sell one product for everything? Two reasons, one clinical and one commercial. Clinically, FDA approval is use-specific: a drug carries different labeled indications, and prescribing outside them is "off-label." Giving weight management its own brand and label let Lilly run the right trials, get the right approval, and market directly to the obesity use. Commercially — and this is the part that hits your wallet — separating the brands let Lilly build different pricing and access programs for each. Diabetes drugs and obesity drugs are covered very differently by insurers; two brands let Lilly meet each market on its own terms. The upshot for you is that the brand name on your prescription isn't a medical choice about which molecule is better. It's a routing decision that determines which coverage rules, savings programs, and cash prices apply.

If you've also been weighing the other big GLP-1 brands, the same logic applies one layer up. Semaglutide is sold as Ozempic (diabetes) and Wegovy (weight loss); tirzepatide is sold as Mounjaro (diabetes) and Zepbound (weight loss). The genuinely different molecules are semaglutide versus tirzepatide — which we compare head-to-head in our Wegovy vs Zepbound guide and at the molecule level in tirzepatide vs semaglutide. Mounjaro versus Zepbound is a different kind of question entirely, because there's no molecule difference to litigate.

Do they work the same for weight loss?

Yes — because they're the same drug. This is the question people most want answered, and the honest answer is almost anticlimactic: tirzepatide is tirzepatide, so at the same dose, in the same person, Mounjaro and Zepbound will do the same thing to appetite, blood sugar, and weight. There is no head-to-head trial of Mounjaro against Zepbound, and there never will be one, because it would be a trial of a drug against itself.

What we do have is strong evidence for how much weight tirzepatide produces. In SURMOUNT-1, the pivotal weight-management trial (Jastreboff et al., NEJM 2022), adults with obesity but without diabetes lost on average about 15% of their body weight at the 5 mg dose and roughly 21% at the 15 mg dose over 72 weeks — among the largest averages ever seen for a weight-loss drug. That's the Zepbound indication's headline evidence, but it's evidence about the molecule, so it describes what Mounjaro's tirzepatide does too.

On the diabetes side, tirzepatide was also tested directly against semaglutide in people with type 2 diabetes in SURPASS-2 (Frías et al., NEJM 2021), where tirzepatide beat semaglutide on both blood-sugar control and weight. That's a real head-to-head — but it's tirzepatide (the Mounjaro/Zepbound molecule) versus semaglutide (the Ozempic/Wegovy molecule), not Mounjaro versus Zepbound.

There's one nuance worth stating plainly so you're not misled by cross-brand weight-loss comparisons online. People sometimes note that "Zepbound" trials show more weight loss than "Mounjaro" trials, and conclude Zepbound is the stronger weight-loss drug. It isn't — the gap is about who was in the trials. Mounjaro's trials studied people with type 2 diabetes, who as a group lose somewhat less weight on GLP-1 drugs than people without diabetes, for reasons related to how diabetes affects metabolism. Zepbound's trials studied people with obesity and mostly no diabetes. Same drug, different populations, slightly different average numbers. If you and your neighbor took the identical dose of the identical molecule, your diabetes status — not the brand name — would be the thing nudging your results.

Bottom line: if your question is "will I lose more weight on Mounjaro or Zepbound," the answer is "neither — they're the same tirzepatide, so pick the one you can actually get and afford." For how much weight tirzepatide tends to produce and how fast, see our realistic results guide. The interesting decisions are everything except efficacy — so let's get to them.

The real difference #1: insurance coverage

This is where the two brands genuinely diverge, and for most people it's the single biggest factor. Because Mounjaro is labeled for type 2 diabetes and Zepbound for obesity, they fall under different parts of how insurers cover drugs — and American health plans treat diabetes and obesity very differently.

Mounjaro (diabetes) is frequently covered by commercial insurance for people who have type 2 diabetes, because diabetes medications are a standard, long-covered category. If you have diabetes and a plan with a typical drug benefit, Mounjaro is often on the formulary, sometimes with prior authorization, and your out-of-pocket cost can be a modest copay rather than the full price.

Zepbound (obesity) is a harder coverage story. Many employer and commercial plans exclude anti-obesity medications entirely, treating weight-loss drugs as outside the benefit even when the same insurer happily covers the identical molecule as Mounjaro for a diabetic member. That's not a quirk — it's the central frustration of obesity medicine right now: the drug works, it's FDA-approved for obesity, and coverage still lags because of how plans historically carved out weight-loss treatment. The NIH's NIDDK overview of obesity medications is a useful plain-language reference on where these drugs sit. Zepbound's newer obstructive sleep apnea indication has opened some additional coverage doors for patients who qualify on that basis, since sleep apnea is a distinct medical condition some plans will cover treatment for.

Medicare adds its own wrinkle. Traditional Medicare Part D has historically been barred from covering drugs used for weight loss, which left Zepbound-for-obesity out — while Mounjaro for diabetes can be covered under Part D for beneficiaries who have diabetes. Coverage policy here is actively evolving (including around the sleep-apnea indication and various bridge arrangements), so check the current rules at Medicare.gov rather than trusting any static summary, including this one.

The coverage paradox, in one sentence

The exact same molecule may be a $25 copay as Mounjaro (because you have diabetes and your plan covers diabetes drugs) and a $500+ cash expense as Zepbound (because your plan excludes weight-loss drugs) — which is why your diagnosis, not the drug, often decides your bill.

The practical takeaway: call your insurer before you decide anything. Ask specifically whether your plan covers Mounjaro (and under what conditions) and whether it covers Zepbound for weight management or sleep apnea. The answer varies enormously plan to plan, and it will tell you more about which brand makes sense for you than any trial result can. For a fuller walkthrough of what GLP-1 treatment actually costs across routes, see our GLP-1 cost guide.

The real difference #2: the cash price

If insurance won't cover your tirzepatide — which is common, especially for weight loss — you're in the self-pay market, and here the two brands price differently. Lilly sells both at a high list price (roughly $1,000–$1,100 a month for either brand at retail without any discount), but almost nobody pays that; the numbers that matter are the manufacturer's self-pay programs, which sell the drug directly at a steep discount, usually as lower-cost vials rather than the pricier auto-injector pens.

Here's a late-2026 snapshot. Treat every figure as a starting point to verify, not a quote — these programs change their prices and terms frequently, and published figures from different sources disagree.

 Mounjaro (self-pay)Zepbound (self-pay)
Retail list price~$1,100+/mo~$1,086/mo
Manufacturer self-pay~$499/mo (reported flat across doses)~$299 (2.5 mg) · ~$399 (5 mg) · ~$449 (higher doses)
Form sold self-payPen / vial depending on programSingle-dose vials
Savings cardRequires commercial insurance (not cash payers)Requires commercial insurance (not cash payers)

Late-2026 snapshot from the manufacturers' official self-pay pages — Zepbound via Lilly's Zepbound site and Mounjaro via Lilly's Mounjaro site. Published prices vary by source and change often; confirm the current figure and refill terms directly before you pay.

Two things stand out. First, for someone paying cash specifically for weight loss, the Zepbound self-pay vials start cheaper — the lowest starting doses run a few hundred dollars a month, versus a flat rate around $499 commonly reported for Mounjaro self-pay. So the "weight-loss brand" is, conveniently, also usually the cheaper cash route for weight loss. Second, the savings cards don't help cash payers: both brands' copay cards require you to have commercial insurance, so they lower a covered patient's copay but do nothing if you're uninsured or your plan excludes the drug. That catches a lot of people off guard.

The honest framing: if you're self-paying for weight management, Zepbound's vial program is usually the intended, lower-cost on-ramp, and there's little reason to pay more for Mounjaro to get the identical molecule. If you have diabetes, the calculus flips, because Mounjaro is the one your insurance is likely to cover — making a covered Mounjaro copay cheaper than any cash Zepbound price. Match the brand to the door that's open to you.

The real difference #3: who can legitimately get which

Because the brands are indication-specific, which one a clinician can appropriately prescribe depends on why you're taking it. This isn't just paperwork — it's the difference between a legitimate prescription and an off-label workaround, and it affects coverage, pharmacy dispensing, and in some cases whether a telehealth program will touch your case at all.

  • You have type 2 diabetes. Mounjaro is the on-label choice, and it's the one your insurance most likely covers. This is the cleanest, usually cheapest path to tirzepatide.
  • You're treating obesity / overweight (no diabetes). Zepbound is the on-label choice. It's what the weight-management trials studied, what the FDA approved for this use, and what the self-pay weight-loss programs are built around.
  • You have moderate-to-severe obstructive sleep apnea with obesity. Zepbound is the one carrying that specific indication; Mounjaro does not. If sleep apnea is your qualifying condition, you'll be prescribed Zepbound.

You'll sometimes hear about people getting "Mounjaro for weight loss" even without diabetes. That's an off-label prescription — legal for a clinician to write using their judgment, but it means you're taking the diabetes brand for an unapproved use, which can complicate coverage (insurers may deny a diabetes drug billed for weight loss) and isn't the intended path now that Zepbound exists specifically for weight management. Before Zepbound launched, off-label Mounjaro was common simply because it was the only tirzepatide available; today there's usually no reason to go that route for weight loss when the on-label, often-cheaper Zepbound exists.

If you're going through an online program, this is a good honesty test of the program itself. A legitimate telehealth clinic takes a real history, matches the right brand to your actual condition, and won't hand you a diabetes drug off-label just to tick a box. Our guide on how to spot a legit online clinic covers the signals that separate a real prescriber from a checkout questionnaire.

Side effects and safety: identical

Since Mounjaro and Zepbound are the same molecule, their side effects and safety profile are the same. There is no "gentler" brand. What you read about tirzepatide side effects applies equally to both, and the brand on the box tells you nothing about how you'll tolerate it.

The common side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting, and indigestion, most pronounced in the first weeks and after each dose increase, and usually easing as your body adjusts. They're the main reason people struggle early, and they're largely manageable with a slow dose titration, smaller meals, and good hydration. Our complete GLP-1 side-effects guide covers each one and exactly how to handle it.

Both brands also carry the same boxed warning — the FDA's most serious — about thyroid C-cell tumors seen in rodent studies. Tirzepatide (under either name) is contraindicated for people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. There are other important precautions (pancreatitis, gallbladder issues, a risk of low blood sugar especially when combined with other diabetes medications, and more), which is exactly why this belongs with a real prescriber who takes your history. The MedlinePlus tirzepatide information lays out the warnings in plain language for either brand.

The practical point: don't choose between the brands on side effects, because there's nothing to choose. If you tolerate one, you tolerate the other, because they're the same thing. Tolerance is about the dose and your own physiology, not the label.

Dosing and how you take it: also identical

Both brands use the same once-weekly injection and the same titration schedule. You start low — 2.5 mg weekly for the first four weeks — then step up to 5 mg, and increase gradually as needed and tolerated through 7.5, 10, 12.5, and up to a maximum of 15 mg. The slow ramp exists to limit the GI side effects, and it's the same for Mounjaro and Zepbound because the drug and doses are the same.

The one practical difference you may notice is device and packaging, which can vary by brand and by whether you're using an insurance-covered pen or a self-pay vial. Mounjaro and Zepbound have been sold as pre-filled auto-injector pens, and the money-saving self-pay routes often use single-dose vials (you draw the dose with a syringe) because vials are cheaper to produce than pens. The medication inside is identical; the delivery hardware is a convenience-and-cost choice, not a clinical one. If drawing from a vial sounds daunting, it's a short learning curve, and legitimate programs walk you through it.

A note on compounded tirzepatide

You'll see online programs advertising compounded tirzepatide at prices well below either brand. It's worth understanding honestly where this stands in 2026, because the landscape changed significantly.

Compounded versions are made by pharmacies rather than by Lilly, and they are not FDA-approved — the FDA doesn't review them for safety, effectiveness, or quality the way it does Mounjaro and Zepbound. During the tirzepatide shortage, federal rules allowed pharmacies to compound it relatively broadly to meet demand. But the FDA declared the tirzepatide shortage resolved in late 2024, and the window for routine large-scale compounding has since closed: by 2025 the FDA was no longer exercising the enforcement flexibility that permitted it, and compounding tirzepatide now rests on much narrower, patient-specific grounds. The FDA's human drug compounding pages and its concerns about unapproved GLP-1 drugs are the authoritative references, and the specifics are evolving through ongoing rulemaking and litigation, so verify the current status before relying on a compounded offer.

What this means practically: for tirzepatide specifically, the cheap compounded route that was everywhere in 2024 is far more restricted now, and a program still pushing compounded tirzepatide hard deserves a careful look at how they're justifying it. For many people, the manufacturer's own self-pay vial programs have become the more sensible low-cost, FDA-approved route. We cover the trade-offs in depth in compounded vs brand vs pills and the legality of compounded GLP-1s.

9.8/10
embody
Best overall value
$49/moflat, locked-in — same at every dose

Compounded GLP-1 injections at a flat, locked-in $49/mo.

Visit embody Read our full review
9.6/10
Eden
Best for flat, predictable pricing
$99/moflat, same at every dose

Compounded GLP-1 at one flat price — $99 semaglutide, $129 tirzepatide, the same every month.

Visit Eden Read our full review

Our picks among online GLP-1 programs. Rankings and reviews are decided independently; we may earn a commission from some providers, which can affect placement but not our scores. How we make money · How we score.

How to choose: a simple decision guide

Strip away the brand marketing and the choice between Mounjaro and Zepbound comes down to your situation, not the drug. Here's the honest decision framework.

Your situationThe brand that fitsWhy
Type 2 diabetes, insuredMounjaroOn-label for diabetes and usually covered — likely your cheapest route.
Obesity / overweight, no diabetesZepboundOn-label for weight management; the intended path and often the cheaper self-pay option.
Obstructive sleep apnea with obesityZepboundOnly Zepbound carries the sleep-apnea indication.
Paying cash for weight lossZepboundSelf-pay vials typically start lower than Mounjaro self-pay, for the identical molecule.
Insurance covers one but not the otherWhichever is coveredA covered copay beats any cash price — let coverage decide.

Notice that none of these rows is about the drug being better or worse — because it isn't. Every row is about access: which indication fits your diagnosis, and which door your insurance or budget leaves open. That's the whole game with Mounjaro versus Zepbound. Once you know your coverage answer and your reason for taking it, the brand chooses itself.

Whichever brand you land on, the thing that actually determines your results is what comes after the prescription: consistent dosing, sensible titration, protein and strength training to protect muscle, and real support when side effects hit or progress stalls. That's where the online program you choose matters far more than Mounjaro-versus-Zepbound ever will — see our full comparison of GLP-1 programs for how the legitimate ones differ on the things that count.

Mounjaro vs Zepbound: frequently asked questions

Are Mounjaro and Zepbound the same drug?

Yes. Both are tirzepatide, made by Eli Lilly, in the same dose strengths (2.5–15 mg). There is no chemical difference between them. The only difference is the FDA-approved use: Mounjaro is approved for type 2 diabetes, and Zepbound is approved for chronic weight management and obstructive sleep apnea. Milligram-for-milligram, they do the same thing in the body.

Is Zepbound better than Mounjaro for weight loss?

No — they're the same molecule, so at the same dose they produce the same weight loss in the same person. Zepbound is simply the brand FDA-approved and marketed for weight loss, which is why its trials (the SURMOUNT program) are the ones that studied weight management. Any difference you see between "Mounjaro" and "Zepbound" weight-loss numbers reflects the different populations studied — Mounjaro's trials enrolled people with diabetes, who tend to lose somewhat less — not a difference in the drug.

Which one is cheaper, Mounjaro or Zepbound?

It depends on your situation. If you have diabetes and insurance, Mounjaro is usually cheaper because it's typically covered, so you pay a copay. If you're paying cash for weight loss, Zepbound's self-pay vials usually start lower than Mounjaro's self-pay price (a late-2026 snapshot puts Zepbound vials around $299–$449/month versus roughly $499/month for Mounjaro self-pay). Both brands' savings cards require commercial insurance and don't help cash payers. Prices change often — verify current figures on the manufacturers' official pages.

Can I get Mounjaro for weight loss if I don't have diabetes?

A clinician can prescribe Mounjaro off-label for weight loss, but it's generally not the intended route now that Zepbound exists and is FDA-approved specifically for weight management. Off-label Mounjaro can complicate insurance (a diabetes drug billed for weight loss may be denied) and usually costs more self-pay than Zepbound. For weight loss without diabetes, Zepbound is the on-label, usually-cheaper choice.

Do Mounjaro and Zepbound have different side effects?

No. Because they're the identical molecule, the side effects and safety profile are the same: mostly gastrointestinal (nausea, diarrhea, constipation), worst early and after dose increases, plus the same boxed warning about thyroid C-cell tumors and the same contraindications. There is no "gentler" brand — tolerance depends on your dose and your own body, not the label.

Can I switch between Mounjaro and Zepbound?

Clinically, switching between them at the same dose is straightforward because it's the same drug at the same strength — a 10 mg dose is a 10 mg dose either way. People often switch for non-medical reasons: a change in insurance coverage, a change in diagnosis, or price. Always make the switch with your prescriber so your dose, supply, and coverage line up, but there's no re-titration needed simply because the brand name changed.

Is compounded tirzepatide a cheaper alternative to both?

It's often advertised cheaper, but compounded tirzepatide is not FDA-approved, and the rules changed substantially after the FDA declared the tirzepatide shortage resolved in late 2024 — routine large-scale compounding is now far more restricted than it was. For many people the manufacturer's own self-pay vial programs have become the more sensible low-cost, FDA-approved route. If a program still leans heavily on compounded tirzepatide, scrutinize how they justify it, and check the current FDA guidance.

The bottom line

Mounjaro and Zepbound are the same tirzepatide — so stop comparing them as drugs and start comparing the doors they open. If you have diabetes, Mounjaro is usually the on-label, covered, cheaper path. If you're treating obesity or sleep apnea, Zepbound is the on-label choice and often the cheaper cash route. Let your diagnosis and your coverage pick the brand; the molecule is identical either way, and what actually drives your results is the support and consistency that come after the prescription.

This article is general information, not medical advice, and not a substitute for a licensed clinician. Tirzepatide is a prescription medication with serious warnings and contraindications; whether it's right for you, and under which brand, is a decision for you and your prescriber. Prices, coverage, and compounding rules described here are a late-2026 snapshot and change frequently — verify current details with the manufacturer, your insurer, and official FDA and Medicare sources before acting.